Role of the HIV-1 V1/V2 domains in the induction of neutralizing antibodies;Papel del dominio V1/V2 de la glucoproteína 120 del virus de la inmunodeficiencia humana de tipo 1 en la inducción de anticuerpos neutralizantes

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue 9, 2009, Pages 523-530

  Granados González, Viviana ^a   Piedrahita, Leidy Diana ^b   Martínez, Marlen ^b   Genin, Christian ^a   Riffard, Serge ^a   Urcuqui Inchima, Silvio ^b  

^a UNIVERSITÉ JEAN MONNET   (France)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

HIV 1; Neutralizing antibodies; V1 V2 domain

Indexed keywords

CARBOHYDRATE; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN V1; VIRUS PROTEIN V2;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; CONFORMATIONAL TRANSITION; GLYCOSYLATION; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MUTATION RATE; NONHUMAN; PROTEIN DOMAIN; RECEPTOR BINDING; REVIEW; VACCINATION;

EID: 70350575357     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2008.02.010     Document Type: Short Survey

References (93)

1. N.L. Letvin, and B.D. Walker Immunopathogenesis and immunotherapy in AIDS virus infections Nat Med 9 7 2003 861 866
2. R. Wyatt, and J. Sodroski The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens Science 280 5371 1998 1884 1888
3. A.K. Pilgrim, G. Pantaleo, O.J. Cohen, L.M. Fink, J.Y. Zhou, J.T. Zhou, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection J Infect Dis 176 4 1997 924 932
4. E.R. Stiehm, L. Mofenson, S. Zolla-Pazner, B. Jackson, N.L. Martin, and A.J. Ammann Summary of the workshop on passive immunotherapy in the prevention and treatment of HIV infection. The Passive Antibody Workshop Participants Clin Immunol Immunopathol 75 1 1995 84 93
5. J.M. Binley, T. Wrin, B. Korber, M.B. Zwick, M. Wang, and C. Chappey Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies J Virol 78 23 2004 13232 13252 (Pubitemid 39507829)
6. D.R. Burton, J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W. Parren, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody Science 266 5187 1994 1024 1027
7. Y. Li, K. Svehla, N.L. Mathy, G. Voss, J.R. Mascola, and R. Wyatt Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants J Virol 80 3 2006 1414 1426
8. L. Wu, Z.Y. Yang, L. Xu, B. Welcher, S. Winfrey, Y. Shao, et al. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope Vaccine 24 23 2006 4995 5002
9. A. Pinter, W.J. Honnen, Y. He, M.K. Gorny, S. Zolla-Pazner, and S.C. Kayman The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection J Virol 78 10 2004 5205 5215
10. A. McKnight, and P.R. Clapham Immune escape and tropism of HIV Trends Microbiol 3 9 1995 356 361
11. P.L. Earl, and B. Moss Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein AIDS Res Hum Retroviruses 9 7 1993 589 594
12. B. Gaschen, J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, et al. Diversity considerations in HIV-1 vaccine selection Science 296 5577 2002 2354 2360
13. A.T. Profy, P.A. Salinas, L.I. Eckler, N.M. Dunlop, P.L. Nara, and S.D. Putney Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual J Immunol 144 12 1990 4641 4647
14. B.R. Starcich, B.H. Hahn, G.M. Shaw, P.D. McNeely, S. Modrow, H. Wolf, et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS Cell 45 5 1986 637 648
15. S. Modrow, B.H. Hahn, G.M. Shaw, R.C. Gallo, F. Wong-Staal, and H. Wolf Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions J Virol 61 2 1987 570 578
16. I. Mondor, S. Ugolini, and Q.J. Sattentau Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans J Virol 72 5 1998 3623 3634
17. J.F. Fortin, R. Cantin, and M.J. Tremblay T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1 J Virol 72 3 1998 2105 2112
18. S. Nisole, B. Krust, C. Callebaut, G. Guichard, S. Muller, J.P. Briand, et al. The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans J Biol Chem 274 39 1999 27875 27884
19. L. Wu, T.D. Martin, R. Vazeux, D. Unutmaz, and V.N. KewalRamani Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission J Virol 76 12 2002 5905 5914
20. J.P. Moore, J.A. McKeating, Y.X. Huang, A. Ashkenazi, and D.D. Ho Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates J Virol 66 1 1992 235 243
21. S. Nisole, and A. Saib Early steps of retrovirus replicative cycle Retrovirology 1 2004 9
22. A.G. Dalgleish, P.C. Beverley, P.R. Clapham, D.H. Crawford, M.F. Greaves, and R.A. Weiss The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 312 5996 1984 763 767
23. H. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, et al. Identification of a major co-receptor for primary isolates of HIV-1 Nature 381 6584 1996 661 666
24. H. Choe, M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates Cell 85 7 1996 1135 1148
25. J.P. Moore Coreceptors: Implications for HIV pathogenesis and therapy Science 276 5309 1997 51 52
26. J.P. Moore, and R.W. Doms The entry of entry inhibitors: A fusion of science and medicine Proc Natl Acad Sci USA 100 19 2003 10598 10602
27. S.A. Gallo, C.M. Finnegan, M. Viard, Y. Raviv, A. Dimitrov, S.S. Rawat, et al. The HIV Env-mediated fusion reaction Biochim Biophys Acta 1614 1 2003 36 50
28. S. Zolla-Pazner Identifying epitopes of HIV-1 that induce protective antibodies Nat Rev Immunol 4 3 2004 199 210
29. H. Markel The search for effective HIV vaccines N Engl J Med 353 8 2005 753 757
30. C. Moog, H.J. Fleury, I. Pellegrin, A. Kirn, and A.M. Aubertin Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals J Virol 71 5 1997 3734 3741
31. M.M. Aasa-Chapman, A. Hayman, P. Newton, D. Cornforth, I. Williams, P. Borrow, et al. Development of the antibody response in acute HIV-1 infection Aids 18 3 2004 371 381
32. S.D. Frost, T. Wrin, D.M. Smith, S.L. Kosakovsky Pond, Y. Liu, and E. Paxinos Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection Proc Natl Acad Sci USA 102 51 2005 18514 18519 (Pubitemid 43011257)
33. J.E. Hansen, H. Clausen, C. Nielsen, L.S. Teglbjaerg, L.L. Hansen, C.M. Nielsen, et al. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: Peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization J Virol 64 6 1990 2833 2840
34. C.N. Scanlan, R. Pantophlet, M.R. Wormald, E. Ollmann Saphire, R. Stanfield, I.A. Wilson, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1 - > 2 mannose residues on the outer face of gp120 J Virol 76 14 2002 7306 7321
35. C.E. Hioe, L. Bastiani, J.E. Hildreth, and S. Zolla-Pazner Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization AIDS Res Hum Retroviruses 14 Suppl 3 1998 S247 S254
36. D.D. Ho, J.A. McKeating, X.L. Li, T. Moudgil, E.S. Daar, N.C. Sun, et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody J Virol 65 1 1991 489 493
37. S. Karwowska, M.K. Gorny, A. Buchbinder, V. Gianakakos, C. Williams, T. Fuerst, et al. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120 AIDS Res Hum Retroviruses 8 6 1992 1099 1106
38. M. Thali, J.P. Moore, C. Furman, M. Charles, D.D. Ho, J. Robinson, et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding J Virol 67 7 1993 3978 3988
39. A.F. Labrijn, P. Poignard, A. Raja, M.B. Zwick, K. Delgado, M. Franti, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 J Virol 77 19 2003 10557 10565
40. S.H. Xiang, N. Doka, R.K. Choudhary, J. Sodroski, and J.E. Robinson Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies AIDS Res Hum Retroviruses 18 16 2002 1207 1217
41. M.K. Gorny, J.P. Moore, A.J. Conley, S. Karwowska, J. Sodroski, and C. Williams Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 J Virol 68 12 1994 8312 8320 (Pubitemid 24362725)
42. M.K. Gorny, C. Williams, B. Volsky, K. Revesz, S. Cohen, V.R. Polonis, et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades J Virol 76 18 2002 9035 9045
43. M.K. Gorny, A.J. Conley, S. Karwowska, A. Buchbinder, J.Y. Xu, E.A. Emini, et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody J Virol 66 12 1992 7538 7542
44. C.F. Scott Jr, S. Silver, A.T. Profy, S.D. Putney, A. Langlois, K. Weinhold, et al. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain Proc Natl Acad Sci USA 87 21 1990 8597 8601
45. A. Trkola, A.B. Pomales, H. Yuan, B. Korber, P.J. Maddon, G.P. Allaway, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG J Virol 69 11 1995 6609 6617
46. M.B. Zwick, A.F. Labrijn, M. Wang, C. Spenlehauer, E.O. Saphire, and J.M. Binley Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41 J Virol 75 22 2001 10892 10905 (Pubitemid 33034579)
47. R. Pantophlet, and D.R. Burton GP120: Target for neutralizing HIV-1 antibodies Annu Rev Immunol 24 2006 739 769
48. A.J. Hessell, L. Hangartner, M. Hunter, C.E. Havenith, F.J. Beurskens, J.M. Bakker, et al. Fc receptor but not complement binding is important in antibody protection against HIV Nature 449 7158 2007 101 104
49. D. Dowbenko, G. Nakamura, C. Fennie, C. Shimasaki, L. Riddle, R. Harris, et al. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies J Virol 62 12 1988 4703 4711
50. J. Goudsmit Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts Aids 2 Suppl 1 1988 S41 S45
51. P.A. Broliden, A. Von Gegerfelt, P. Clapham, J. Rosen, E.M. Fenyo, B. Wahren, et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins Proc Natl Acad Sci USA 89 2 1992 461 465
52. G. Scala, X. Chen, W. Liu, J.N. Telles, O.J. Cohen, M. Vaccarezza, et al. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera J Immunol 162 10 1999 6155 6161
53. C.E. Parker, L.J. Deterding, C. Hager-Braun, J.M. Binley, N. Schulke, and H. Katinger Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5 J Virol 75 22 2001 10906 10911 (Pubitemid 33031557)
54. E. Coeffier, J.M. Clement, V. Cussac, N. Khodaei-Boorane, M. Jehanno, M. Rojas, et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein Vaccine 19 7-8 2000 684 693
55. C.F. Barbas 3rd, E. Bjorling, F. Chiodi, N. Dunlop, D. Cababa, T.M. Jones, et al. Recombinant human fab fragments neutralize human type 1 immunodeficiency virus in vitro Proc Natl Acad Sci USA 89 19 1992 9339 9343
56. C.K. Leonard, M.W. Spellman, L. Riddle, R.J. Harris, J.N. Thomas, and T.J. Gregory Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells J Biol Chem 265 18 1990 10373 10382
57. A. Trkola, M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 J Virol 70 2 1996 1100 1108
58. D.A. Calarese, C.N. Scanlan, M.B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition Science 300 5628 2003 2065 2071
59. A.J. McMichael, and T. Hanke HIV vaccines 1983-2003 Nat Med 9 7 2003 874 880
60. M.S. Fung, C.R. Sun, W.L. Gordon, R.S. Liou, T.W. Chang, W.N. Sun, et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 J Virol 66 2 1992 848 856
61. K. Javaherian, A.J. Langlois, C. McDanal, K.L. Ross, L.I. Eckler, C.L. Jellis, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein Proc Natl Acad Sci USA 86 17 1989 6768 6772
62. J. Goudsmit, C. Debouck, R.H. Meloen, L. Smit, M. Bakker, D.M. Asher, et al. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees Proc Natl Acad Sci USA 85 12 1988 4478 4482
63. J.R. Mascola, S.W. Snyder, O.S. Weislow, S.M. Belay, R.B. Belshe, D.H. Schwartz, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group J Infect Dis 173 2 1996 340 348
64. A.J. Conley, M.K. Gorny, J.A. Kessler 2nd, L.J. Boots, M. Ossorio-Castro, S. Koenig, et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D J Virol 68 11 1994 6994 7000
65. M.K. Gorny, K. Revesz, C. Williams, B. Volsky, M.K. Louder, C.A. Anyangwe, et al. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope J Virol 78 5 2004 2394 2404
66. E.G. Cormier, and T. Dragic The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor J Virol 76 17 2002 8953 8957
67. P.D. Kwong, R. Wyatt, Q.J. Sattentau, J. Sodroski, and W.A. Hendrickson Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus J Virol 74 4 2000 1961 1972
68. R. Wyatt, N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, et al. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions J Virol 67 8 1993 4557 4565
69. C.C. Huang, M. Tang, M.Y. Zhang, S. Majeed, E. Montabana, R.L. Stanfield, et al. Structure of a V3-containing HIV-1 gp120 core Science 310 5750 2005 1025 1028
70. K. Chakraborty, V. Durani, E.R. Miranda, M. Citron, X. Liang, W. Schleif, et al. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies Biochem J 399 3 2006 483 491
71. A. Koito, G. Harrowe, J.A. Levy, and C. Cheng-Mayer Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization J Virol 68 4 1994 2253 2259
72. P. Westervelt, D.B. Trowbridge, L.G. Epstein, B.M. Blumberg, Y. Li, B.H. Hahn, et al. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo J Virol 66 4 1992 2577 2582
73. N. Sullivan, M. Thali, C. Furman, D.D. Ho, and J. Sodroski Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody J Virol 67 6 1993 3674 3679
74. K. Toohey, K. Wehrly, J. Nishio, S. Perryman, and B. Chesebro Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread Virology 213 1 1995 70 79
75. L. Stamatatos, M. Wiskerchen, and C. Cheng-Mayer Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication AIDS Res Hum Retroviruses 14 13 1998 1129 1139
76. R. Wyatt, J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding J Virol 69 9 1995 5723 5733
77. N. Sullivan, Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization J Virol 72 6 1998 4694 4703
78. S. Vijh-Warrier, E. Murphy, I. Yokoyama, and S.A. Tilley Characterization of the variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV-1 Mol Immunol 32 14-15 1995 1081 1092
79. S.V. Warrier, A. Pinter, W.J. Honnen, M. Girard, E. Muchmore, and S.A. Tilley A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody J Virol 68 7 1994 4636 4642
80. S. Vijh-Warrier, A. Pinter, W.J. Honnen, and S.A. Tilley Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site J Virol 70 7 1996 4466 4473
81. Z. Wu, S.C. Kayman, W. Honnen, K. Revesz, H. Chen, S. Vijh-Warrier, et al. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: Role of glycosylation in the correct folding of the V1/V2 domain J Virol 69 4 1995 2271 2278
82. A. Pinter, W.J. Honnen, P. D'Agostino, M.K. Gorny, S. Zolla-Pazner, and S.C. Kayman The C108 g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates J Virol 79 11 2005 6909 6917
83. R. Rong, F. Bibollet-Ruche, J. Mulenga, S. Allen, J.L. Blackwell, and C.A. Derdeyn Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection J Virol 81 3 2007 1350 1359
84. C.P. Krachmarov, W.J. Honnen, S.C. Kayman, M.K. Gorny, S. Zolla-Pazner, and A. Pinter Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1 J Virol 80 14 2006 7127 7135
85. C.D. Rizzuto, R. Wyatt, N. Hernández-Ramos, Y. Sun, P.D. Kwong, W.A. Hendrickson, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding Science 280 5371 1998 1949 1953
86. X. Wei, J.M. Decker, S. Wang, H. Hui, J.C. Kappes, X. Wu, et al. Antibody neutralization and escape by HIV-1 Nature 422 6929 2003 307 312
87. M.K. Gorny, L. Stamatatos, B. Volsky, K. Revesz, C. Williams, X.H. Wang, et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles J Virol 79 8 2005 5232 5237
88. D.D. Ho, M.S. Fung, Y.Z. Cao, X.L. Li, C. Sun, T.W. Chang, et al. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody Proc Natl Acad Sci USA 88 20 1991 8949 8952
89. J. Cao, N. Sullivan, E. Desjardin, C. Parolin, J. Robinson, and R. Wyatt Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein J Virol 71 12 1997 9808 9812 (Pubitemid 27492434)
90. T. Wolk, and M. Schreiber N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization Med Microbiol Immunol 195 3 2006 165 172
91. P.D. Kwong, M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, S. Majeed, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites Nature 420 6916 2002 678 682
92. Y.B. Kim, D.P. Han, C. Cao, and M.W. Cho Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies Virology 305 1 2003 124 137
93. C. Krachmarov, A. Pinter, W.J. Honnen, M.K. Gorny, P.N. Nyambi, S. Zolla-Pazner, et al. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking J Virol 79 2 2005 780 790